Hikma appoints Rebecca Hall as CFO: what it means for Hikma stock

Published on 10/13/2026 at 07:10 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Rebecca Hall joins Hikma in Q1 2027 and replaces a board director on December 31, 2026. For Hikma stock this means an October 20, 2026 R&D seminar and a November 5, 2026 trading update.

Key points in brief

Hikma appointed Rebecca Hall as CFO on September 24, 2026, with her start planned for Q1 2027.
Hikma reported first-half 2026 revenue of USD 1.73 billion, up 4.2 percent year over year.
The last Lang & Schwarz price was EUR 19.35 on October 12, 2026 at 11:00 p.m. CEST.
Six analysts rated Hikma stock a Buy, with an average target of GBp 2,085.83.
Hikma trades on the LSE under ticker HIK.L.

Fotorealistische sterile Pharma-Produktionslinie mit Injektionsfläschchen und Edelstahlanlagen — Hikma Pharmaceuticals PLC GB00B128J450 zeigt moderne Injektions-Produktionslinie in sterilem Pharmawerk mit Edelstahlanlagen, Illustration mit AI erstellt.

Hikma appointed Rebecca Hall as Chief Financial Officer and executive director on September 24, 2026, with her start planned for Q1 2027. As Hikma reported, Hall will replace Khalid Nabilsi on the board, while Nabilsi is scheduled to step down on December 31, 2026.

Three dated milestones shape the story

On August 6, 2026, Hikma reported first-half revenue of USD 1.73 billion, up 4.2 percent from the first half of 2025, according to Hikma. On September 16, 2026, the company launched Glucentra as the first generic semaglutide available to patients in Saudi Arabia, and on September 24, 2026, it named Hall as CFO, per Hikma.

What does the CFO change mean?

Hall brings more than 20 years of experience from ViiV Healthcare and GSK, while Hikma keeps Areb Kurdi as acting CFO until Hall joins in Q1 2027, according to Hikma. For investors, the transition is linked to a business that reported 4.2 percent first-half revenue growth and continued to emphasize investment in complex products and manufacturing capacity.

MarketBeat said on October 7, 2026, that six analysts rated the shares a Buy and that the average price target was GBp 2,085.83. The same report cited targets from GBp 1,870 at Citigroup to GBp 2,100 at Berenberg, while its quoted 200-day moving average was GBp 1,495.66, according to MarketBeat.

Two dates now matter

Hikma scheduled its first R&D investor seminar for October 20, 2026, covering group R&D, respiratory, nasal, semi-solids and liquids. The next scheduled trading update is November 5, 2026, according to Hikma.

Hikma stock stays tied to execution

The last Lang & Schwarz price was EUR 19.35 on October 12, 2026 at 11:00 p.m. CEST. On the LSE, the finance quote showed a last price of GBp 1,629 on October 12, 2026, with a 52-week range of GBp 1,187 to GBp 1,865. The further course of trading is shown by the continuously updated real-time quote of Hikma stock.